E pili ana ʻo Galvus i nā lāʻau lapaʻau i hōʻike ʻia i ka hopena hypoglycemic i hua ʻia. ʻO ka mea hana nui a ka lāʻau lapaʻau ʻo Vildagliptin.
Hoʻohana ʻia ka lāʻau lāʻau e hoʻomaʻamaʻa i ke kōpaʻa koko a lawe ʻia e nā mea maʻi me ka maʻi maʻi.
Ka hoʻonohonoho, hoʻokuʻu i ke ʻano a me ka hana pharmacological
ʻO nā papa hana nui o kēia lāʻau lapaʻau nā papa. ʻO ka inoa inoa honua he Vildagliptin, ʻo Galendo ka inoa kālepa.
ʻO ka hōʻailona nui no ka lawe ʻana i ka lāʻau lapaʻau ka hiki ʻana o ke ʻano maʻi diabetes type 2 i loko o kahi kanaka. Wahi a ka hāmeʻa e pili ana i nā lāʻau lapaʻau hypoglycemic i lawe ʻia e nā mea maʻi e hōʻemi i ka ʻaila o ke kō i loko o ke koko.
ʻO ka mea nui o ka lāʻau lapaʻau ka vildagliptin. ʻO kona ʻona he 50 mg. ʻO nā kumumanaʻi hou: nā magnesium stearate a me ka sodium carboxymethyl starch. ʻO ka hui pū me ka lactose anhydrous a me ka cellulose microcrystalline pū kekahi.
Loaʻa ka lāʻau lapaʻau ma ke ʻano o nā papa i lawe ʻia ma ke alo. Hoʻohālikelike ka laulā o nā papa mai ke keʻokeʻo a ʻulaʻula. ʻO ka papa o nā papa i ka pōpō a me ka mālie i ka loaʻa ʻana o nā bevels ma nā kihi. Ma nā ʻaoʻao ʻelua he papa inoa nā huaʻōlelo: "NVR", "FB".
Loaʻa iā Galvus i ke ʻano o nā blisters no 2, 4, 8 a i ʻole 12 i hoʻokahi pahu. 1 kīwī he 7 a 14 mau papa o Galvus (ʻike i ke kiʻi).
ʻO ka mea Vildagliptin, ʻo ia kahi o ka lāʻau lapaʻau, ka mea e hōʻeuʻeu i ka apana islet o ka pancreas, e hoʻohiolo ana i ka hana a nā kaila DPP-4 a hoʻonui i ka hoʻowalewale o ka cells-cell i ka glucose. Hoʻonui kēia i nā mea huna gli-hilinaʻi o ka insulin.
E hoʻonui ʻia ka ʻike ʻana o nā β-cell i ka ʻike ʻana i ka pae o ko lākou hōʻeha mua. I ka mea ʻaʻole loaʻa ka maʻi o ka maʻi diabetes, ʻaʻole ia e hoʻowalewale ʻia ka ʻike huna ʻana ma muli o ka lawe ʻana i ka lāʻau. Hoʻonui ka waiwai i ka hoʻoponopono ʻana i ka glucagon.
Ke lawe nei ʻo Vildagliptin, e emi ka pae o ka lipids i ka plasma koko. ʻO ka hoʻohana ʻana i ka lāʻau lapaʻau ma ke ʻano o ka monotherapy, e like me ka Metformin, no nā lā 84-365 e alakaʻi i ka emi ʻana o ka pae o ka glucose a me ka hemoglobin glycated i loko o ke koko.
Lapaʻau lāʻau
Hoʻokomo ʻia ka lāʻau lapaʻau i loko o kahi ʻōpū ʻūhā i loko o 105 mau minuke. Ke lawe nei i ka lāʻau lapaʻau ma hope o ka ʻai ʻana, e emi ana kona hāmeʻe a hiki ke hiki i 2.5 mau hola.
Hōʻike ʻia ʻo Vildagliptin e ka wikiwiki o ka lawe ʻana. ʻO ka bioavailability o ka lāʻau lapaʻau ka 85%. ʻO ka nānā ʻana o ka hana ikaika o ka lāʻau i loko o ke koko ma muli o ka nui i lawe ʻia.
Hōʻike ʻia ka lāʻau lapaʻau e kahi haʻahaʻa haʻahaʻa o ka hoʻopili ʻana i nā protein plasma. ʻO kona helu he 9.3%.
Hoʻokuʻu ʻia ka waiwai mai ke kino o ka mea maʻi me ka biotransformation. Hōʻike ʻia ʻo ia i 69% o ka nui i lawe ʻia i ka lāʻau. ʻO 4% o ka lāʻau lapaʻau i lawe ʻia ma ka hydrolysis amide.
ʻO 85% o ka lāʻau ke hoʻopau ʻia mai ke kino e nā ʻōpū, ʻo ke koena 15% e nā ʻāpana. ʻO ka hapalua o ka ola o ka lāʻau lapaʻau e pili ana i nā hola 2-3. ʻO ka pharmacokinetics o Vildagliptin ʻaʻole i hilinaʻi i ka paona, ke kāne a me ka pūʻulu, ma muli o ka mea e lawe ai i ka lāʻau lapaʻau.
I nā poʻe maʻi me ka hana pūpū hemahema, ʻike ʻia kahi lohi i ka bioavailability o ka lāʻau. Me kahi ʻano hōʻole iki, hoʻemi ʻia ka mākaʻi bioavailability e ka 8%, me kahi ʻano awelika - ma 20%.
Ma nā hiʻohiʻona paʻakikī, hōʻemi kēia hōʻailona ma ka 22%. ʻO ka hōʻemi a hoʻonui paha i ka bioavailability i loko o 30% he mau mea maʻamau a ʻaʻole pono i ka hoʻoponopono hoʻoponopono ʻia.
I ka poʻe maʻi me ka maʻi renal impaired e like me ka mea e hoʻopiʻi ana i ka maʻi, koi ʻia kahi hoʻoponopono ʻana. I ka poʻe ma luna o 65, he piʻi nui o ka bioavailability o ka lāʻau i ka 32%, ka mea i manaʻo he maʻamau. ʻAʻole ʻike nā ʻikepili ma nā ʻano lāʻau pharmacokinetic o ka lāʻau i nā keiki.
Nā hōʻailona a me nā contraindications
Hoʻohana ʻia ʻo Galvus no ka maʻi type o ka lā 2 ma nā hihia penei:
- me ka hana ikaika o ka hoʻomaʻamaʻa a me ka meaʻai, hoʻohana ʻia i hui pū ʻia me Metformin;
- i ka hui pū me Insulin, Metformin, me ka maikaʻi ʻole o kēia mau lāʻau;
- ʻoiai he lāʻau lapaʻau hoʻokahi, inā ʻaʻole hoʻomehana ka mea maʻi i ka Metformin, inā ʻo ka mea ʻai me ke ʻano o nā hoʻomaʻamaʻa ʻaʻole i hopena i kahi hopena;
- i ka hui pū ʻana me nā mea Metformin a me nā pākia sulfonylurea, inā he mālama mua ma mua o nā hua i hōʻike ʻia, ʻaʻole i hāʻawi i kahi hopena;
- i loko o ka hoʻolālā o ka hoʻomehana me ka hoʻohana ʻana iā Thiazolidinedione, Sulfonylurea a me nā mea waiwai o ia, ʻo Metformin, Insulin, inā ʻo ka mālama ʻana me ka mea i hōʻike ʻia i hoʻokaʻawale ʻia, e like me ka meaʻai me ka hana, ʻaʻole i hāʻawi i kahi hopena.
ʻO nā kumumanaʻo ka lawe ʻana i ka lāʻau lapaʻau nā:
- lactic acidosis;
- hapai
- liilii;
- nā kaha lactase;
- maʻi mellitus type 1;
- kuʻe o ka pāpaho;
- intolerance galactose;
- ka hewa ʻole o kahi kumu maʻi o ka papa IV;
- ka hoʻomaloka pilikino ʻana i nā waiwai e hoʻomālamalama ai i ka lāʻau;
- maʻiʻo ketoacidosis maʻi (ʻelua a me ke koʻikoʻi);
- makahiki i 18 makahiki.
Nā ʻōkuhi no ka hoʻohana ʻana i ka lāʻau lapaʻau
ʻO ka make ʻana o kēia lāʻau lapaʻau ka hilinaʻi i nā hiʻohiʻona o ke kino o ka mea maʻi.
Palapala o nā kaha i ʻōlelo ʻia i ka lāʻau.
| Monotherapy | Hoʻopili i ka insulin me ka thiazolidinedione a me ka metformin | I ka hui pūʻana me nā mea hoʻohui o ka olelonlurea a me ka metformin | I ka hui pū ʻana me sulfonylurea (derivatives ona) |
|---|---|---|---|
| 50 mg hoʻokahi a ʻelua paha i kēlā me kēia lā (maximum dosis 100 mg) | 50-100 mg hoʻokahi a ʻelua paha ma ka lā | 100 mg i ka lā | 50 mg hoʻokahi i kēlā me kēia 24 hola |
I ka hana ʻole o ke kahe o ke kōʻai koko koko mai ke kiʻekiʻe loa o ka 100 mg, kahi ʻāpana hana hou o nā mea like me hypoglycemic like.
ʻAʻole pili ʻo Galvus i ka ʻai. Pono pono ka hoʻoponopono ʻana o ka maʻi maʻi no nā maʻi me ka ʻoi ʻana o ka hana hakahaka hanalaha o kahi pae paʻaha. Pono ka ʻona nui loa e 50 mg i kēlā me kēia lā. No nā māhele ʻē aʻe o ka mea maʻi, ʻaʻole pono ka hoʻoponopono ʻana o ka lāʻau lapaʻau.
Nā ʻōlelo kikoʻī
ʻAʻole kōkua ʻo Galvus i kēia mau kānaka:
- ka pilikia ʻana mai ka puʻuwai ʻeha ma kahi ʻano paʻakikī o ka papa IV;
- ka uhaki ʻana i ka ate;
- me ka pilikia ʻana ma ka hana kīnā ʻole o kēlā me kēia.
Hoʻopau maikaʻi ʻia ka lāʻau no:
- nā wahine hāpai;
- hānai makuahine;
- keiki malalo o 18 makahiki;
- nā mea maʻi me ka maʻi māmā.
Hoʻohana ʻia me ka mālama pono ʻana i nā maʻi me nā hōʻailona o ka pancreatitis aʻokiʻoki, a me nā mea maʻi e pili ana i ka hope me ka pau ʻole o ka naʻau a pau ma ke ʻano he hoʻomaʻemaʻe.
Pono e hoʻohana i ka lāʻau lapaʻau me ka mālama ʻana i nā mea maʻi me ka papa o ka maʻi III ʻano paʻakikī.
ʻO ka hoʻokolohua ʻōhumu o ka sulfonylurea a me ka galvusa hiki ke alakaʻi i ka hypoglycemia. Inā kūpono, hoʻemi i ka ʻōpū.
Nā hopena ʻaoʻao a me ka overdose
ʻO nā hopena ʻaoʻao mai ka lawe ʻana i ka lāʻau lapaʻau ke loaʻa pinepine ʻole. ʻO ka manawa pokole ko lākou helehelena ke koi ʻole a ʻaʻole pono e hoʻopau ʻia.
Me ka monotherapy, ʻike pinepine ʻia nā mea i ʻike ʻia.
- ʻʻAla
- ka māla ʻana
- constipation
- nā kuʻi;
- nasopharyngitis.
Ke hui pū ʻia me Metformin, hiki i kēia lā:
- hoʻomoe;
- ʻʻAla
- poʻomanaʻo.
Ke hoʻohui nei i ka lāʻau lapaʻau me nā huapalapala o ka sulfonylurea, hiki i nā mea aʻe:
- constipation
- ʻʻAla
- nasopharyngitis;
- poʻomanaʻo.
Ke hoʻohui me ka insulin, hiki i kēia:
- asenaiia;
- nā ninia
- hypoglycemia;
- mea ʻalaʻawa
- nā kuʻi;
- pāhawewe;
- ka nui e hoʻohiki.
Me ka hoʻokolohua ʻōwili ʻana me ka thiazolidinedione, hiki i ka edema peripheral a me ka loaʻa ʻana o ka paona .. Ma nā hihia maʻamau, urticaria, pancreatitis a meʻeha loa nā maʻi hepatitis ma hope o ka hoʻokō ʻana.
ʻO kahi overdose o ka lāʻau lapaʻau i kekahi mau hihia e alakaʻi i ke kuni, ka ʻehaʻeha o ka a me ka pupuhi.
Nā hanana like like ʻole e hoʻopau i ka 400 mg o Galvus i ka lā. 200 mg o ka lāʻau lapaʻau e ʻae ʻia e nā maʻi maʻi. I kahi papa o 600 mg, ke kīwī nei ka mea maʻi i nā mea kuʻikahi, aʻo ka pae o ka myoglobin a me kekahi nui o nā enzyme o ke koko e hoʻonui.
Hoʻomaka maikaʻi ʻia nā hōʻailona o kahi make overdose ma hope o ka hoʻokuʻu ʻana o ka lāʻau lapaʻau.
Nā Kūleʻa Kūʻai a me nā Analog
Hōʻike ʻia ka lāʻau lapaʻau e kahi haʻahaʻa o nā hōʻiliʻili lāʻau, hiki iā ʻoe ke lawe i ka lāʻau lapaʻau me nā ʻano like ʻole o nā enzyme a me nā inhibitors.
I ka wā e hui pū ai me Warfarin, Amlodipine, Glibenclamide, Digoxin, ʻaʻole i hoʻokau ʻia kahi pilina koʻikoʻi ma waena o kēia mau lāʻau a me Galvus.
Ua hōʻike ʻia ʻo Galvus:
- Vildagliptin;
- Vipidia;
- Kalepui Met;
- Onglisa;
- Trazenta;
- Hoavius.
Loaʻa iā Galvus Met kahi hoʻohālikelike kūloko, a me ia: Glimecomb, Combogliz Prolong, Avandamet.
ʻO nā mea wikiō e pili ana i ka hiki ʻana mai, ka mālama ʻana a me ka pale ʻana i ka maʻi diabetes:
ʻO ka manaʻo o nā kauka
Mai nā loiloi o nā kauka, hiki ke hopena i ka ʻāpono ʻia loa ʻo Galvus e nā aneane āpau, akā no kona nāwaliwali a me ka pono o ka hoʻohana ʻana i nā lāʻau e hoʻohiolo ai i ka hilo.
He manawa lōʻihi kā Galvus i ka noi ma Rūsia. E maikaʻi ana ka huahana a maikaʻi ʻole. Hoʻomaʻamaʻa maikaʻi ʻo Galvus i nā maʻi, he mau haʻahaʻa haʻahaʻa no ka hypoglycemia. He kūpono ia i nā poʻe maʻi kahiko, ʻo ka hāʻawi ʻana i ka mau māka i hōʻailona ʻia i loko o ka hana renal i ka wā ʻelemakule. Ua hōʻike ʻia nā noiʻi hiki ke lawe ʻia Galvus i ʻāpana o ke ʻano nephroprotective.
Mikhaleva O.V., endocrinologist
ʻOiai ka maikaʻi o ka waiwai o Galvus, kahi e hoʻemi ai i ka paona o nā mea maʻi, ua ʻano maʻalahi kona hopena i ke kō. Hoʻomaʻa pinepine, pono ka lāʻau lapaʻau i kahi hoʻokomo pilikino me nā lāʻau lapaʻau hypoglycemic ʻē aʻe.
Shvedova A.M., endocrinologist
ʻO ke kumukūʻai o nā kālā ma nā wahi like ʻole mai 734-815 rubles. ʻO ka analogue nui o ka lāʻau (Galvus Met) aia ma ka wahi o 1417-1646 rubles.
